Astellas Pharma Gmbh

Yamanouchi Pharmaceutical Company Ltd.

Hiromu Kondo

Kazuhiro Sako

Toyohiro Sawada

Hiroyuki Kojima

Shunsuke Watanabe

Keiichi Yoshihara

Yuuki Tsutsui

Shigeo Takemura

Kiyo Nakanishi

The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (C/Cratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (C) to the maximum plasma tamsulosin concentration after the administration (C) is about 0.4 or more.

Sustained release pharmaceutical composition

The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

Pharmaceutical composition for oral use with improved absorption

Growing community of inventors

Shizuoka-ken, Japan

Hiromu Kondo